Pharmacogenomics in Psychiatry Practice: The Value and the Challenges

Area of Science:

• Pharmacogenetics
• Neuroscience
• Clinical Psychiatry

Background:

• Cytochrome P450 (CYP450) enzyme activity is crucial for psychotropic drug metabolism.
• Genetic and non-genetic factors cause significant inter-individual and inter-ethnic variability in CYP450 activity.
• This variability impacts treatment efficacy and adverse drug reactions in psychiatric patients.

Purpose of the Study:

• To review common CYP450 isoenzymes involved in psychotropic drug metabolism.
• To examine ethnic variations in CYP450 activity and their effect on neurotransmitters (dopamine, serotonin).
• To discuss the influence of non-genetic factors (smoking, age, pregnancy) and HLA genotypes on drug response and adverse effects.

Main Methods:

• Literature review of CYP450 enzymes, psychotropic medications, and genetic variations.
• Analysis of publicly available data (e.g., 1000 Genomes Project) on variant prevalence across ethnicities.
• Examination of associations between genetic variants, drug metabolism, and adverse effects like obesity and metabolic syndrome.

Main Results:

• CYP450 activity variations, primarily due to genetic polymorphism, correlate with individualized clinical outcomes.
• Adverse psychiatric medication effects are linked to specific human leukocytic antigen (HLA) variants.
• Limited research exists on genetic variations affecting endogenous neuropeptide metabolism.

Conclusions:

• Pharmacogenetics implementation in psychiatry is valuable for predicting treatment outcomes and managing adverse effects.
• Further research is needed to enhance the predictability of gene variants for precision psychiatric therapies.
• Understanding ethnic prevalence of key variants is essential for global precision medicine approaches.